D
Dana P. Goldman
Researcher at University of Southern California
Publications - 381
Citations - 16877
Dana P. Goldman is an academic researcher from University of Southern California. The author has contributed to research in topics: Health care & Population. The author has an hindex of 62, co-authored 377 publications receiving 15247 citations. Previous affiliations of Dana P. Goldman include George Washington University & Dana Corporation.
Papers
More filters
Journal Article
Simulating the impact of medical savings accounts on small business.
TL;DR: The authors' simulations suggest that MSAs will provide a limited impetus to businesses that do not currently cover insurance, however, MSAs could be desirable to workers in firms that already offer HMOs or standard FFS plans.
Journal ArticleDOI
Association between use of warfarin with common sulfonylureas and serious hypoglycemic events: retrospective cohort analysis
John A. Romley,Cynthia L. Gong,Anupam B. Jena,Dana P. Goldman,Bradley R. Williams,Anne L. Peters +5 more
TL;DR: A substantial positive association was seen between use of warfarin with glipizide/glimepiride and hospital admission/emergency department visits for hypoglycemia and related diagnoses, particularly in patients starting warfarIn, suggesting the possibility of a significant drug interaction between these medications.
Journal ArticleDOI
Prescription Medication Abuse and Illegitimate Internet-Based Pharmacies
TL;DR: The nature of the problem and its magnitude are described, the challenges to federal and private efforts to combat illegitimate online pharmacies are discussed, and strategies for physicians to recognize and minimize the unwarranted effects of the availability of these medications on the Internet are outlined.
Health Status and Medical Treatment of the Future Elderly
TL;DR: RAND was contracted with CMS to develop models to project how changes in health status, disease, and disability among the next generation of elderly will affect future spending.
Journal ArticleDOI
Medicaid Cost Control Measures Aimed At Second-Generation Antipsychotics Led To Less Use Of All Antipsychotics
TL;DR: Comparative effectiveness research should guide physicians and health plans on appropriate first treatments, while prior authorization policies should focus on moving patients to appropriate second-line therapies when necessary.